Apr 27, 2023 / 07:30AM GMT
Operator
Welcome to BioArctic Q1 report 2023. (Operator Instructions)
Now I will hand the conference over to CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead.
Gunilla Osswald - BioArctic AB(publ)-CEO
Good morning, and welcome to BioArctic's presentation for the first quarter of 2023. I'm Gunilla Osswald, and I'm CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson; and our Chief Medical Officer, Tomas Odergren.
We will give an update on BioArctic and on lecanemab, and focus on the great start of this year with the approval in the U.S. by the accelerated pathway and the submission of applications for full market approval of lecanemab in 3 continents. These submissions are based on the groundbreaking results for lecanemab in the Clarity AD Phase III study in Early Alzheimer's disease. And I think it's really exciting that lecanemab, or Leqembi as it's named in the U.S., now it's available for patients in the U.S., and we'll talk more about that here today.
Next slide,
Q1 2023 BioArctic AB Earnings Call Transcript
Apr 27, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers